Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 177

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing

Open access
Cieslik, Marcin, Chugh, Rashmi, Wu, Yi-Mi, Wu, Ming, Brennan, Christine, Lonigro, Robert, Su, Fengyun, Wang, Rui, Siddiqui, Javed, Mehra, Rohit, Cao, Xuhong, Lucas, David, Chinnaiyan, Arul M., Robinson, Dan·2015·Genome Research

Abstract

RNA-seq by poly(A) selection is currently the most common protocol for whole transcriptome sequencing as it provides a broad, detailed, and accurate view of the RNA landscape. Unfortunately, the utility of poly(A) libraries is greatly limited when the input RNA is degraded, which is the norm for research tissues and clinical samples, especially when specimens are formalin-fixed. To facilitate the use of RNA sequencing beyond cell lines and in the clinical setting, we developed an exome-capture transcriptome protocol with greatly improved performance on degraded RNA. Capture transcriptome libraries enable measuring absolute and differential gene expression, calling genetic variants, and detecting gene fusions. Through validation against gold-standard poly(A) and Ribo-Zero libraries from intact RNA, we show that capture RNA-seq provides accurate and unbiased estimates of RNA abundance, uniform transcript coverage, and broad dynamic range. Unlike poly(A) selection and Ribo-Zero depletion, capture libraries retain these qualities regardless of RNA quality and provide excellent data from clinical specimens including formalin-fixed paraffin-embedded (FFPE) blocks. Systematic improvements across key applications of RNA-seq are shown on a cohort of prostate cancer patients and a set of clinical FFPE samples. Further, we demonstrate the utility of capture RNA-seq libraries in a patient with a highly malignant solitary fibrous tumor (SFT) enrolled in our clinical sequencing program called MI-ONCOSEQ. Capture transcriptome profiling from FFPE revealed two oncogenic fusions: the pathognomonic NAB2-STAT6 inversion and a therapeutically actionable BRAF fusion, which may drive this specific cancer's aggressive phenotype.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/gr.189621.115

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 177

Metadata

Authors
Cieslik, M., Chugh, R., Wu, Y.-M., Wu, M., Brennan, C., Lonigro, R., Su, F., Wang, R., Siddiqui, J., Mehra, R., Cao, X., Lucas, D., Chinnaiyan, A. M., & Robinson, D.
Venue
Genome Research
Published
2015-08-07
Volume
25
Issue
9
Pages
1372-1381
ISSN
  • 1088-9051 (ISSN-L)
  • 1549-5469
OpenAlex
W2104806879
Cited by
177
References
14
Type
posted content
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. https://app.cochat.ai/papers/10.1101/gr.189621.115
The paper
Cieslik, M., Chugh, R., Wu, Y.-M., Wu, M., Brennan, C., Lonigro, R., Su, F., Wang, R., Siddiqui, J., Mehra, R., Cao, X., Lucas, D., Chinnaiyan, A. M., & Robinson, D. (2015). The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing. Genome Research. https://doi.org/10.1101/gr.189621.115

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.